• Rezolute priced an underwritten offering of common stock and pre-funded warrants expected to raise approximately $100 million in gross proceeds.
• The offering includes 22,040,976 common shares priced at $3.87 each.
• Pre-funded warrants cover up to 3,800,000 shares at $3.869 per warrant, with a $0.001 per-share exercise price.
• Closing is expected on or about November 16, 2026, subject to customary conditions.
• Net proceeds will support ersodetug commercialization preparation, working capital and general corporate purposes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rezolute Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611130619PRIMZONEFULLFEED9877148) on November 13, 2026, and is solely responsible for the information contained therein.